Page last updated: 2024-09-05

erlotinib hydrochloride and nadp

erlotinib hydrochloride has been researched along with nadp in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (nadp)	Trials (nadp)	Recent Studies (post-2010) (nadp)
4,353	786	3,033	21,608	25	3,484

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, W; Hu, Y; Peng, P; Qiu, N; Sheng, R; Yuan, Y	1
Bartom, E; Bi, Y; Burant, CF; Calvert, AE; Chalastanis, A; Chandel, NS; Davuluri, RV; Dubrovskyi, O; Horbinski, C; Hua, Y; Hurley, LA; James, CD; Kachman, M; Kouri, FM; May, JL; Mazar, AP; Mishra, RK; Peter, ME; Schiltz, GE; Stegh, AH; Wu, Y; Zheng, H	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and nadp

Article	Year
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. Bioorganic & medicinal chemistry, 2014, Dec-15, Volume: 22, Issue:24 Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship	2014
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell reports, 2017, 05-30, Volume: 19, Issue:9 Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Histones; Isocitrate Dehydrogenase; Ketoglutaric Acids; Lipids; Methylation; Mice; Mice, SCID; Molecular Targeted Therapy; Mutation; NADP; Neoplastic Stem Cells; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Messenger	2017

Article

Year

Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.

Bioorganic & medicinal chemistry, 2014, Dec-15, Volume: 22, Issue:24

Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship

2014

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Cell reports, 2017, 05-30, Volume: 19, Issue:9

Topics: Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Histones; Isocitrate Dehydrogenase; Ketoglutaric Acids; Lipids; Methylation; Mice; Mice, SCID; Molecular Targeted Therapy; Mutation; NADP; Neoplastic Stem Cells; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Messenger

2017